73
Views
5
CrossRef citations to date
0
Altmetric
Original Research

LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis

, , , , , & show all
Pages 1299-1306 | Published online: 11 Feb 2021

References

  • Cohen P, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X30638582
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
  • Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2 Suppl):S5–S10. doi:10.1016/j.ygyno.2010.01.02420304221
  • Phianmongkhol Y, Suwan N, Srisomboon J, Kietpeerakool C. Knowledge about human papillomavirus infection and cervical cancer prevention among nurses in Chiang Mai University Hospital, Thailand. Asian Pac J Cancer Prev. 2011;12(3):823–825.21627391
  • Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–532. doi:10.1016/S0140-6736(13)62218-724192252
  • de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. doi:10.1002/ijc.3071628369882
  • Rodríguez-Carunchio L, Soveral I, Steenbergen RD, et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG. 2015;122(1):119–127. doi:10.1111/1471-0528.1307125229645
  • Ibeanu OA. Molecular pathogenesis of cervical cancer. Cancer Biol Ther. 2011;11(3):295–306. doi:10.4161/cbt.11.3.1468621239888
  • Crafton SM, Salani R. Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin Ther. 2016;38(3):449–458. doi:10.1016/j.clinthera.2016.02.00726926322
  • Peng L, Yuan X, Jiang B, Tang Z, Li G-C. LncRNAs: key players and novel insights into cervical cancer. Tumor Biol. 2016;37(3):2779–2788. doi:10.1007/s13277-015-4663-9
  • Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271–286.26721498
  • Liu H, Lu S, Guo Z, et al. lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer. J Investig Med. 2019;68:jim–2019.
  • Das R, Gregory PA, Fernandes RC, et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Res. 2017;77(4):1021–1034. doi:10.1158/0008-5472.CAN-16-252928011622
  • Biewenga P, van der Velden J, Mol BW, et al. Prognostic model for survival in patients with early stage cervical cancer. Cancer. 2011;117(4):768–776. doi:10.1002/cncr.2565820922801
  • Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27(4):e43–e43. doi:10.3802/jgo.2016.27.e4327171673
  • Zhang X, Wei C, Li J, Liu J, Qu J. MicroRNA-194 represses glioma cell epithelial‑to‑mesenchymal transition by targeting Bmi1. Oncol Rep. 2017;37(3):1593–1600. doi:10.3892/or.2017.537628098896
  • Luo L, Zhang Y, He H, Chen C, Zhang B, Cai M. LncRNA FEZF1-AS1 sponges miR-34a to upregulate Notch-1 in glioblastoma. Cancer Manag Res. 2020;12:1827–1833. doi:10.2147/CMAR.S24053132210625